The Technical Analyst
BIOLASE Inc [BIOL]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
BIOLASE Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.14% $0.145
America/New_York / 26 apr 2024 @ 11:14
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.71 mill |
| EPS: | -29.44 |
| P/E: | 0 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 32.52 mill |
| Avg Daily Volume: | 5.76 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.117 - 0.175 ( +/- 19.86%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-28 | Goldman Sachs Group Inc | Buy | 0 | Common Stock |
| 2023-06-08 | Yale Kenneth P. | Buy | 502 404 | Restricted Stock Unit |
| 2023-06-08 | Somerman Martha J. Dds, Phd | Buy | 518 429 | Restricted Stock Unit |
| 2023-06-08 | Roper Jess | Buy | 512 821 | Restricted Stock Unit |
| 2023-06-08 | Oloughlin Kathleen T | Buy | 502 404 | Restricted Stock Unit |
| INSIDER POWER |
|---|
| 99.63 |
| Last 95 transactions |
| Buy: 20 716 278 | Sell: 14 318 495 |
Forecast:
12:53 - $0.146
Live Trading Signals (every 1 min)
Forecast
1: 11:23 - $0.145
Forecast 2: 12:13 - $0.145
Forecast 3: 12:53 - $0.146
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.145 (-2.14% ) |
| Volume | 0.224 mill |
| Avg. Vol. | 5.76 mill |
| % of Avg. Vol | 3.88 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BIOL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BIOL
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
Latest Press Releases
2024-03-21 16:05:00 - Press Release
Biolase Reports Full-year 2023 Results; Expects Continued Revenue Growth In 2024
Lake forest, ca / accesswire / march 21, 2024 / biolase, inc. (nasdaq:biol), the globally recognized leader in dental laser technology, who previously announced its preliminary financial results for the fourth quarter and full year ended december 31, 2023, today reported its financial results for the quarter and full year. 2023 full-year highlights achieved revenue growth despite industry headwinds and a challenging interest rate environment throughout 2023.
2024-03-14 06:30:00 - Press Release
Biolase To Report Fourth Quarter And Full Year 2023 Results On March 21, 2024
Lake forest, ca / accesswire / march 14, 2024 / biolase, inc. (nasdaq:biol), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on thursday, march 21, 2024, after the close of the u.s. financial markets and will host a conference call and webcast that day at 4:30 p.m. et / 1:30 p.m.
2024-02-22 06:30:00 - Press Release
Biolase Launches State-of-the-art All-tissue Laser System To Accelerate Adoption Of Lasers In Dentistry
Waterlase iplus premier edition™ is being unveiled at the chicago midwinter meeting 2024 lake forest, ca / accesswire / february 22, 2024 / biolase, inc. (nasdaq:biol), the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, waterlase iplus premier edition™, and will be debuting it at the chicago midwinter meeting 2024 from february 22nd to 24th at booth 4608. the waterlase iplus premier edition™ is an extraordinary update to the industry-leading waterlase iplus and represents the pinnacle of innovation in dental care.
2024-02-20 06:30:00 - Press Release
Biolase Announces First Quarter 2024 Webinar Series 'lets Talk Dental'
Lake forest, ca / accesswire / february 20, 2024 / biolase, inc. (nasdaq:biol), the global leader in dental lasers, remains committed to expanding its educational offerings through its web portal, enabling dental clinicians to elevate their standard of dental care and improve patient outcomes through laser technology. "let's talk dental," a free webinar series focused on a variety of topics covering all dental disciplines, kicked off the year with a webinar on january 18, 2024, hosted by dr. paul chang, a periodontist and prosthodontist with a private practice in mckinney, texas.
2024-02-15 14:45:00 - Press Release
Biolase, Inc. Announces Closing Of $7.0 Million Public Offering
Lake forest, ca / accesswire / february 15, 2024 / biolase, inc. (nasdaq:biol), the global leader in dental lasers, today announced the closing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one class a warrant to purchase one share of common stock, and one class b warrant to purchase one share of common stock. each unit was sold at an effective public offering price of $0.44.
Latest News
2024-03-14 06:30:00 - Accesswire
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.
2024-02-09 08:35:36 - Benzinga
Top 5 Health Care Stocks That Are Preparing To Pump In February - CNS Pharma (NASDAQ:CNSP), Biolase (NASDAQ:BIOL)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-08-04 07:52:43 - Benzinga
Top 5 Health Care Stocks That Could Blast Off In August - Biolase (NASDAQ:BIOL), Allarity Therapeutics (NASDAQ:ALLR)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-05-12 09:20:41 - InvestorPlace
Why Is Biolase (BIOL) Stock Down 13% Today?
Biolase (NASDAQ: BIOL ) stock is taking a beating on Friday following the release of its earnings report for the first quarter of 2023. The bad news for investors in BIOL stock is the company's earnings per share of -18 cents for the period.
2023-04-20 06:00:00 - PennyStocks
Penny Stock Risk Assessment: Evaluating Potential Investments
How to evaluate penny stocks using risk management techniques The post Penny Stock Risk Assessment: Evaluating Potential Investments appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-28 21:31:05 - Seeking Alpha
BIOLASE, Inc. (BIOL) Q4 2022 Earnings Call Transcript
BIOLASE, Inc. (NASDAQ:BIOL ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Todd Kehrli - IR John Beaver - President and CEO Jennifer Bright - CFO Conference Call Participants Bruce Jackson - The Benchmark Company Frank Takkinen - Lake Street Capital Markets Anthony Vendetti - Maxim Group Edward Woo - Ascendiant Capital Operator Greetings. Welcome to the BIOLASE 2022 Fourth Quarter and Full Year Financial Results Call.
2023-03-13 06:30:00 - PRNewsWire
BIOLASE TO REPORT FOURTH QUARTER AND FULL YEAR 2022 RESULTS ON MARCH 28, 2023
LAKE FOREST, Calif. , March 13, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release fourth quarter and full year 2022 financial and operating results on Tuesday, March 28, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m.
2023-02-16 18:00:00 - PRNewsWire
BIOLASE TO PRESENT AT THE THIRD ANNUAL WINTER WONDERLAND BEST IDEAS VIRTUAL INVESTOR CONFERENCE
LAKE FOREST, Calif. , Feb. 16, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has been invited to present at the Third Annual Winter Wonderland Best Ideas Virtual Investor Conference being held February 21–24, 2023.
2022-11-14 06:30:00 - PRNewsWire
BIOLASE to Participate in the Benchmark Discovery One-on-One Investor Conference on December 1, 2022 in New York
LAKE FOREST, Calif. , Nov. 14, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to participate in the 11th Annual Benchmark Discovery One-on-One Investor Conference taking place December 1, 2022 in New York City.
2022-11-10 20:19:13 - Seeking Alpha
BIOLASE, Inc. (BIOL) Q3 2022 Earnings Call Transcript
BIOLASE, Inc. (NASDAQ:BIOL ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Todd Kehrli - Investor Relations John Beaver - President and Chief Executive Officer Jennifer Bright - Chief Financial Officer Conference Call Participants Kyle Bauser - Lake Street Capital Markets Anthony Vendetti - the Maxim Group Bruce Jackson - The Benchmark Company Operator Good day and welcome to the BIOLASE Third Quarter 2022 Financial Results Conference Call. Please note, this call is being recorded.